Efficacy and safety of systemic isotretinoin treatment for moderate to severe acne (insights from the real-life clinical setting).
Ersilia TolinoNevena SkrozaProietti IlariaAlessandra MambrinVeronica BalduzziAnna MarchesielloPatrizia MaddalenaSimone MicheliniSalvatore VolpeNicoletta BernardiniConcetta PotenzaPublished in: Dermatologic therapy (2020)
Acne is a chronic inflammatory relapsing disease that affect predominantly adolescents, with scarring as a frequent sequele. Early and appropriate therapy allows better management of the disease, longer remission, scars risk reduction, and improvement of quality of life. According to therapeutic algorithm, systemic isotretinoin can be used in severe acne and also in moderate forms resistant to other systemic treatments. The aims of this real-life observational study were to determine and compare the effectiveness of isotretinoin evaluated by Global Acne Grading System and Acne Quality of Life in moderate and in severe acne, correlation between efficacy and cumulative dose of isotretinoin, tolerability, and recurrence rate. Moreover, the differences in efficacy and tolerability between male and female patients were compared. The treatment with systemic isotretinoin led to an improvement in acne severity and quality of life in all observed subjects.
Keyphrases
- hidradenitis suppurativa
- drug induced
- end stage renal disease
- early onset
- randomized controlled trial
- high intensity
- multiple sclerosis
- young adults
- ejection fraction
- newly diagnosed
- stem cells
- machine learning
- systematic review
- chronic kidney disease
- physical activity
- prognostic factors
- oxidative stress
- deep learning
- clinical trial
- rheumatoid arthritis
- peritoneal dialysis
- study protocol
- african american